Indivior (INDV) CSO granted RSUs and performance stock units

Rhea-AI Filing Summary

Indivior Pharmaceuticals, Inc. Chief Scientific Officer Christian Heidbreder reported equity awards in the form of stock-based compensation. On February 10, 2026, he acquired, via grant, 33,622 restricted stock units of common stock at a price of $0 and now directly holds 190,762 common shares.

On February 9, 2026, he was also granted 132,565 performance stock units at a price of $0. These performance stock units relate to a conditional award whose performance conditions were certified on February 9, 2026 and are scheduled to vest on March 3, 2026, subject to continued employment. The RSUs vest in three equal annual installments beginning February 10, 2027.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Heidbreder Christian

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	33,622	$0.00	--
Grant/Award	Performance Stock Units	132,565	$0.00	--

Holdings After Transaction: Common Stock — 190,762 shares (Direct); Performance Stock Units — 132,565 shares (Direct)

Footnotes (1)

1. Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock, vesting in three equal annual installments beginning on February 10, 2027, the first anniversary of the grant, subject to the Reporting Person's continued service with the Issuer. On March 3, 2023, the Reporting Person was granted a conditional award for 132,565 shares, subject to satisfaction of performance conditions, which were certified on February 9, 2026. The award vests, subject to continued employment conditions, on March 3, 2026.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Heidbreder Christian

(Last) (First) (Middle)

10710 MIDLOTHIAN TURNPIKE

SUITE 125

(Street)

NORTH CHESTERFIELD VA 23235

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Indivior Pharmaceuticals, Inc. [ INDV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/10/2026		A		33,622(1)	A	$0	190,762	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Stock Units	$0	02/09/2026		A		132,565		03/03/2026(2)	(2)	Common Stock	132,565	$0	132,565	D

Explanation of Responses:

1. Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock, vesting in three equal annual installments beginning on February 10, 2027, the first anniversary of the grant, subject to the Reporting Person's continued service with the Issuer.

2. On March 3, 2023, the Reporting Person was granted a conditional award for 132,565 shares, subject to satisfaction of performance conditions, which were certified on February 9, 2026. The award vests, subject to continued employment conditions, on March 3, 2026.

Remarks:

Exhibit 24 Power of Attorney

	/s/Alice Givens, Power of Attorney	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did INDV Chief Scientific Officer Christian Heidbreder report?

Christian Heidbreder reported receiving equity awards in Indivior Pharmaceuticals, Inc. stock. He acquired 33,622 restricted stock units of common stock and 132,565 performance stock units at a grant price of $0, reflecting stock-based compensation rather than open-market purchases.

How many Indivior (INDV) common shares does Christian Heidbreder hold after this Form 4?

After the reported grant, Christian Heidbreder directly beneficially owns 190,762 shares of Indivior common stock. This figure includes his holdings following the award of 33,622 restricted stock units reported as an acquisition at a price of $0 per share.

What are the vesting terms of the 33,622 restricted stock units reported by INDV’s CSO?

The 33,622 restricted stock units each represent a right to receive one Indivior common share. They vest in three equal annual installments starting February 10, 2027, the first anniversary of the grant, contingent on Christian Heidbreder’s continued service with the company.

What are the details of the 132,565 performance stock units granted to the INDV executive?

The 132,565 performance stock units stem from a conditional award originally granted March 3, 2023. Performance conditions were certified on February 9, 2026, and the award is scheduled to vest on March 3, 2026, subject to continued employment with Indivior Pharmaceuticals, Inc.

Are the reported INDV insider awards open-market purchases or compensation grants?

Both the 33,622 common stock units and 132,565 performance stock units are compensation grants. The Form 4 identifies them with transaction code “A” for grants or awards, and each was granted at a price of $0 per unit, rather than bought on the open market.